Global Influenza Drugs Market Size study & Forecast, by Drug Type (Ribavirin, Oseltamivir, Relenza (Zanamivir), Peramivir, Influenza Vaccines), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel) and Regional Analysis, 2023-20

Global Influenza Drugs Market Size study & Forecast, by Drug Type (Ribavirin, Oseltamivir, Relenza (Zanamivir), Peramivir, Influenza Vaccines), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel) and Regional Analysis, 2023-2030

Global Influenza Drugs Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Influenza is a common viral infection that, if not carefully and rapidly treated, can be deadly. It affects the nose, throat, and lungs badly and is an infectious respiratory infection. The best way to prevent the flu, which is brought on by influenza viruses, is to be vaccinated annually. Runny nose, exhaustion, aches in the muscles, headaches, fever, and congestion are the most typical influenza symptoms. The key factors driving the market growth is increasing incidence and prevalence of influenza, rising healthcare expenditure worldwide, and increasing awareness and concern for public health that anticipated to support the market growth during forecast period 2023-2030.

Moreover, the increasing prevalence of influenza can have several implications that may contribute to the growth of the Influenza Drugs Market. As the number of influenza cases rises, there anticipated to be an increased demand for medications to alleviate symptoms and reduce the severity of the illness. This increased demand can drive pharmaceutical companies to develop and market new and more effective influenza drugs. According to a World Health Organisation study performed from January 24 to February 6, 2022, around 12,368 persons tested positive with influenza viruses. Of them, 8,423 (68.1%) were diagnosed with influenza A and 3,945 (31.9%) with influenza B. Furthermore, 171 (6.4%) were infected with influenza A (H1N1), whereas 2,483 (93.6%) were infected with influenza A (H3N2). Additionally, rise in R&D investments for discovery of new drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of drug development, and side effects associated with antiviral therapy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Influenza Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising high incidence of influenza, increasing awareness, advancements in treatment, and supportive government initiatives. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing prevalence of influenza, growing awareness and healthcare infrastructure, rising government initiatives, and strong pharmaceutical industry presence.

Major market player included in this report are:
FACCUSA Laboratories Inc
Lonza Group Ltd
Bristol-Myers Squibb
Pfizer Inc.
GlaxoSmithKline plc
Novo Nordisk A/S
Sanofi
Cipla Limited
Bayer AG
Banting Medical Inc.

Recent Developments in the Market:
In November 2020, Shionogi & Co., Ltd. announced that its Licence Partner F. Hoffmann-La Roche Ltd., which holds worldwide rights to Xofluza® except in Japan and Taiwan, has received FDA approval for a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone who has influenza (known as post-exposure prophylaxis). The first single-dose influenza drug licenced for post-exposure prophylaxis is Xofluza.

Global Influenza Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Drug Type, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Type:
Ribavirin
Oseltamivir
Relenza (Zanamivir)
Peramivir
Influenza Vaccines
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Channel
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
FACCUSA Laboratories Inc
Lonza Group Ltd
Bristol-Myers Squibb
Pfizer Inc.
GlaxoSmithKline plc
Novo Nordisk A/S
Sanofi
Cipla Limited
Bayer AG
Banting Medical Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.